Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia

Natarajan, Harivenkatesh; David, Darling Chellathai; Haribalaji, Natarajan; Sudhakar, Muthiah Kothandaramanujam

doi:10.1177/1074248413518968

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20) Treatment with atorvastatin, in particular, has been shown to be superior in preventing and treating cardiovascular disease. [21][22][23] Correlation analysis suggested that Tregs frequency and function positively are correlated with left ventricular ejection fraction, but negatively correlated with left ventricular end-diastolic dimension and Nterminal pro-brain natriuretic peptide (NT-proBNP) in patients with CHF. 24) Zhang, et al 25) demonstrated that atorvastatin treatment was associated with reduced all-cause mortality and readmission rate for heart failure (HF), and the superiority of statin therapy was significant in CHF patients younger than 65 years.…”

mentioning

confidence: 99%

Changes of Naturally Occurring CD4+CD25+ FOXP3+ Regulatory T Cells in Patients With Acute Coronary Syndrome and the Beneficial Effects of Atorvastatin Treatment

Wang¹,

Wang

Li³

et al. 2015

Int. Heart J.

View full text Add to dashboard Cite

SummaryTo determine the number and function of naturally occurring CD4+ regulatory T cells (nTregs) in patients with acute coronary syndrome (ACS) and to determine the effects of a low dose of atorvastatin treatment (20 mg/day) on nTregs.Patients with ACS were randomly divided into a group receiving conventional therapy (n = 60) or conventional therapy supplemented with atorvastatin (20 mg/day) (n = 60). A group of healthy volunteers that did not suffer from ACS was used as controls (n = 60). T lymphocytes were isolated from ACS patients, both before and 4 weeks after treatment, or control patients and the percentage of nTregs was determined by flow cytometry. Serum levels of cytokines were determined by enzyme-linked immunosorbent assays. A mixed lymphocyte reaction was used to determine the ability of nTregs to inhibit proliferation of effector T cells. Quantitative PCR and Western blot were used to analyze (forkhead box P3) FOXP3 mRNA transcript levels and the expression of FOXP3 protein.In ACS patients, the percentage and inhibitory properties of nTregs were reduced, IFN-γ and hsCRP levels were increased, and IL-10 and TGF-β 1 levels were lowered. Atorvastatin treatment increased the percentage and inhibitory ability of nTregs, decreased serum IFN-γ and hsCRP levels, and decreased IL-10 and TGF-β 1 levels, as compared with the non-atorvastatin group.Our findings suggest that nTregs play an atheroprotective role in atherosclerosis. The inhibitory effects of atorvastatin on inflammation in ACS may be due to its beneficial effects on nTregs and restoration of immune homeostasis. (Int Heart J 2015; 56: 163-169)

show abstract

mentioning

confidence: 99%

Changes of Naturally Occurring CD4+CD25+ FOXP3+ Regulatory T Cells in Patients With Acute Coronary Syndrome and the Beneficial Effects of Atorvastatin Treatment

Wang¹,

Wang

Li³

et al. 2015

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…The level of serum HDL-c was elevated by XKA (1.5 g/kg) by 24.5 %. TC-HDL-c ratio is an independent predictors of coronary heart disease (CHD) events [ 22 ]. In XKA (1.5 g/kg and 0.75 g/kg) treatment groups, TC-HDL-c ratio of KKAy mice was significantly lowered by 12.0 % and 9.2 %, respectively.…”

Section: Resultsmentioning

confidence: 99%

Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches

Yang

Wang

Zhang

et al. 2015

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundXiao-Ke-An (XKA) is a Chinese medicine widely used for treating type 2 diabetes mellitus (T2D). It is composed of eight herbal medicines traditionally used for T2D, including Rehmannia glutinosa Libosch, Anemarrhena asphodeloides Bunge, Coptis chinensis Franch, etc. The aim of the present study was to investigate the antidiabetic effects of XKA with both conventional and holistic omics approaches.MethodsThe antidiabetic effect of XKA was first investigated in 3T3-L1 cells to study the effect of XKA on adipogenesis in vitro. Oil Red O staining was performed to determine the lipid accumulation. The intracellular total cholesterol (TC) and triglyceride (TG) contents in XKA treated 3T3-L1 cells were also evaluated. The therapeutic effects of XKA was further evaluated in KKAy mice with both conventional and holistic omics approaches. Body weight, fasting and non-fasting blood glucose, and oral glucose tolerance were measured during the experiment. At the time of sacrifice, serum was collected for the measurement of TG, TC, high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c). The liver, kidney, spleen, pancreas, heart and adipose tissues were harvested and weighted. The liver was used for further microarray experiment. Omics approaches were adopted to evaluate the holistic rebalancing effect of XKA at molecular network level.ResultsXKA significantly inhibited adipogenic differentiation, lowered the intracellular TC and TG contents in 3T3-L1 cells. XKA improved the glucose homeostasis and lipid metabolism, ameliorated insulin resistance in KKAy mice. Futhermore, XKA also exhibited effective therapeutic effects by reversing the molecualr T2D disease network from an unbalanced state.ConclusionsThis study investigated the antidiabetic effects of XKA with both conventional and holistic omics approaches, providing both phenotypic evidence and underlying action mechanisms for the clinical use of XKA treating T2D.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-015-0785-2) contains supplementary material, which is available to authorized users.

show abstract

Statins and Fibrates: Should They Be Recommended?

Chruściel

Mikhailidis

Tóth

et al. 2015

Combination Therapy in Dyslipidemia

View full text Add to dashboard Cite

Efficacy and Safety of Alternate Day Therapy With Atorvastatin and Fenofibrate Combination in Mixed Dyslipidemia

Cited by 5 publications

References 20 publications

Changes of Naturally Occurring CD4<sup>+</sup>CD25<sup>+</sup> FOXP3<sup>+</sup> Regulatory T Cells in Patients With Acute Coronary Syndrome and the Beneficial Effects of Atorvastatin Treatment

Changes of Naturally Occurring CD4<sup>+</sup>CD25<sup>+</sup> FOXP3<sup>+</sup> Regulatory T Cells in Patients With Acute Coronary Syndrome and the Beneficial Effects of Atorvastatin Treatment

Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches

Statins and Fibrates: Should They Be Recommended?

Contact Info

Product

Resources

About